Healthcare
TherapeuticsMD, Inc.(TXMD)
Live Price
Offline$2.27
-0.87% today
1Y Change
+104.50%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $20.00M
- Revenue Growth
- +71.6%
- EPS Growth
- +74.1%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TherapeuticsMD, Inc. (TXMD) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $2.27 and up 104.5% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +71.6%, EPS growth of +74.1%, a dividend yield of 0.0%. What stands out right now is revenue +71.6%, EPS +74.1%, free cash flow +235.2% with operating margin -128.8% and ROIC -11.8%. Valuation sits in the middle of the pack at price/sales 7.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TXMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+71.6% vs +7.6% peer median
Operating Margin
Below sector median
-128.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +71.6% and EPS at +74.1%, with operating margin around -128.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | โ | +1.0% | +4.5% | +13.4% |
2026 Mar 30, 2026 | +99.1% | +1.5% | +1.5% | +5.5% |
2025 Nov 12, 2025 | โ | -3.6% | -1.8% | +9.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TXMD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TXMD Max Drawdown
-34.30%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TXMD and SPY.
Company Overview
TherapeuticsMD, Inc.
NASDAQ Global Select
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ร-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
- Leadership
- Marlan D. Walker
- IPO Date
- May 9, 2007
- Employees
- 1
- Street Address
- 951 Yamato Road
- Mailing
- Boca Raton, FL, 33431
- Region
- Boca Raton, FL, US
- Reporting Currency
- USD
- Investor Line
- 561 961 1900
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 7.9
- Price/Book
- 0.9
Growth
- Revenue
- +71.6%
- EPS
- +74.1%
- Free Cash Flow
- +235.2%
Profitability
- Gross Margin
- 70.0%
- Operating Margin
- -128.8%
- Net Margin
- -18.8%
- ROE
- -2.1%
- ROIC
- -11.8%
Balance Sheet
- Debt/Equity
- 0.19
- Current Ratio
- 3.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.